Baloch K, Chen L, et al. Equilibrative nucleoside transporter 1 expression in primary human hepatocytes is highly variable and determines uptake of ribavirin. Antivir Chem Chemother. 2017;25(1):2–10.

Article  PubMed  PubMed Central  Google Scholar 

Giovannetti E, Leon LG, et al. A specific inhibitor of lactate dehydrogenase overcame the resistance toward gemcitabine in hypoxic mesothelioma cells, and modulated the expression of the human equilibrative transporter-1. Nucleosides Nucleotides Nucleic Acids. 2016;35(10–12):643–51.

Article  CAS  PubMed  Google Scholar 

Zafar M, Naydenova Z, et al. Extended exposure to substrate regulates the human equilibrative nucleoside transporter 1 (hENT1). Nucleosides Nucleotides Nucleic Acids. 2016;35(10–12):631–42.

Article  CAS  PubMed  Google Scholar 

Wu L, Shi W, et al. High expression of the human equilibrative nucleoside transporter 1 gene predicts a good response to decitabine in patients with myelodysplastic syndrome. J Transl Med. 2016;14(1):66.

Article  PubMed  PubMed Central  Google Scholar 

Yamada R, Mizuno S, et al. Human equilibrative nucleoside transporter 1 expression in endoscopic ultrasonography-guided fine-needle aspiration biopsy samples is a strong predictor of clinical response and survival in the patients with pancreatic ductal adenocarcinoma undergoing gemcitabine-based chemoradiotherapy. Pancreas. 2016;45(5):761–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cass CE, Paterson AR. Mediated transport of nucleosides in human erythrocytes. Accelerative exchange diffusion of uridine and thymidine and specificity toward pyrimidine nucleosides as permeants. J Biol Chem. 1972;247(10):3314–20.

Article  CAS  PubMed  Google Scholar 

Kuttesch JF Jr, Robins MJ, et al. Renal transport of 2’-deoxytubercidin in mice. Biochem Pharmacol. 1982;31(21):3387–94.

Article  CAS  PubMed  Google Scholar 

Belt JA, Welch AD. Transport of uridine and 6-azauridine in human lymphoblastoid cells Specificity for the uncharged 6-azauridine molecule. Mol Pharmacol. 1983;23(1):153–8.

CAS  PubMed  Google Scholar 

Daniels G. The Augustine blood group system, 48 years in the making. Immunohematology. 2016;32:100–3.

Article  PubMed  Google Scholar 

Damaraju VL, Weber D, et al. Selective inhibition of human equilibrative and concentrative nucleoside transporters by BCR-ABL Kinase Inhibitors: identification of key hENT1 amino acid residues for interaction with BCR-ABL kinase inhibitorS. J Biol Chem. 2016;291(36):18809–17.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Panigrahi R, Dash S. ENT1 and treatment of viral diseases. Oncotarget. 2015;6(32):32281–2.

Article  PubMed  PubMed Central  Google Scholar 

Aseervatham J, Tran L, et al. The role of flexible loops in folding, trafficking and activity of equilibrative nucleoside transporters. PLoS ONE. 2015;10(9):e0136779.

Article  PubMed  PubMed Central  Google Scholar 

Wan H, Zhu J, et al. SLC29A1 single nucleotide polymorphisms as independent prognostic predictors for survival of patients with acute myeloid leukemia: an in vitro study. J Exp Clin Cancer Res. 2014;33(1):90.

Article  PubMed  PubMed Central  Google Scholar 

Tavano F, Fontana A, et al. Modeling interactions between Human Equilibrative Nucleoside Transporter-1 and other factors involved in the response to gemcitabine treatment to predict clinical outcomes in pancreatic ductal adenocarcinoma patients. Pancreatology. 2014;12(1):1–11.

Google Scholar 

Ormanns S, Heinemann V, et al. Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: translational results from the AIO-PK0104 phase III study with the clone SP120 rabbit antibody. Eur J Cancer. 2014;50(11):1891–9.

Article  CAS  PubMed  Google Scholar 

Zhu Y, Qi M, et al. Human equilibrative nucleoside transporter 1 predicts survival in patients with pancreatic cancer treated with gemcitabine: a meta-analysis. Genet Test Mol Biomark. 2014;18(5):306–12.

Article  CAS  Google Scholar 

Furihata T, Mizuguchi M, et al. Identification of primary equilibrative nucleoside transporter 1 mRNA isoforms resulting from alternative promoter usage in human hepatocytes. Drug Metab Pharmacokinet. 2014;29(4):325–32.

Article  CAS  PubMed  Google Scholar 

Liu ZQ, Liu ZQ, et al. Prognostic value of human equilibrative nucleoside transporter1 in pancreatic cancer receiving gemcitabin-based chemotherapy: a meta-analysis. PLoS ONE. 2014;9(1):e87103.

Article  PubMed  PubMed Central  Google Scholar 

Mohelnikova-Duchonova B, Melichar B. Human equilibrative nucleoside transporter 1 (hENT1): do we really have a new predictive biomarker of chemotherapy outcome in pancreatic cancer patients? Pancreatology. 2013;13(6):558–63.

Article  CAS  PubMed  Google Scholar 

Wei CH, Gorgan TR, et al. A meta-analysis of gemcitabine biomarkers in patients with pancreaticobiliary cancers. Pancreas. 2013;42(8):1303–10.

Article  CAS  PubMed  Google Scholar 

Suzuki Y, Homma M, et al. Impact of solute carrier family 29 member 1 (SLC29A1) single nucleotide polymorphisms on mRNA expression in peripheral blood mononuclear cells. Biol Pharm Bull. 2013;36(1):144–6.

Article  CAS  PubMed  Google Scholar 

Daniels G. Augustine blood group system and equilibrative nucleoside transporter 1. Transfus Med Hemother. 2022;49:25–9.

Article  PubMed  Google Scholar 

Millard GM, McGowan EC, et al. A proposed new low-frequency antigen in the Augustine blood group system associated with a severe case of hemolytic disease of the fetus and newborn. Transfusion. 2018;58:1320–2.

Article  PubMed  Google Scholar 

Yao SY, Ng AM, et al. Nucleobase transport by human equilibrative nucleoside transporter 1 (hENT1). J Biol Chem. 2011;286(37):32552–62.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guillén-Gómez E, Pinilla-Macua I, et al. New role of the human equilibrative nucleoside transporter 1 (hENT1) in epithelial-to-mesenchymal transition in renal tubular cells. J Cell Physiol. 2012;227(4):1521–8.

Article  PubMed  Google Scholar 

Xu Z, Li SZ. Research progress of erythrocyte blood group antigen. Clin Hematol Transfus Testing. 2016;29(4):345–50.

CAS  Google Scholar